煤焦沥青诱发大鼠肺癌的实验研究——Ⅱ.形态学观察

本文对煤焦沥青诱发大鼠肺癌过程中的病理形态学所见作了报道。整个过程可以分为三个阶段:1.异物反应阶段;2.异常增生和鳞状化生阶段;3.癌肿发生发展阶段。文中对每一个阶段的病理组织学改变做了详细描述。煤焦沥青诱发的大鼠肺癌的特征如下:1.癌肿全都发生在肺的周边部位;2.绝大多数癌肿的组织类型都是高分化鳞状细胞癌;3.多发性,数个至数十个大小不等的肿块布满全肺;4.癌变各个不同阶段的改变可在同一肺脏中出现;5.转移癌较少见。     

白血病肺部并发症的影像学分析

目的　分析白血病肺部并发症影像学特点 ,提高诊断白血病肺部并发症的水平。方法　分析 2 0 0例白血病肺部并发症的影像学特点。结果　并发症的致病因素 :单一细菌感染占 3 3 .5% (67例 ) ,细菌混合感染占 3 5% (70例 ) ,真菌感染占 3 .5% (7例 ) ,真菌细菌混合感染占 5% (10例 ) ,致病菌不明占 2 3 % (46例 )。影像学表现 :肺纹理改变 84例 (42 % ) ,肺实质病变 116例 (58% ) ,胸膜改变 2 9例 (14 .5% ) ,胸腔积液 19例 (9.5% ) ,肺门或纵隔改变 40例 (2 0 % )。结论　白血病肺部并发症以感染为多见 ,诊断应结合临床和实验室检查。此外治疗后复查对照亦有助于鉴别     

CT增强扫描在评价NSCLC血管生成中的临床意义

目的　探讨非小细胞肺癌 (NSCLC)血管内皮生长因子 (VEGF)的表达水平与CT增强程度的关系 ,从影像学角度评价肿瘤血管生成在肺癌诊断、治疗及淋巴结转移中的临床价值。方法　对 30例NSCLC病人进行动态螺旋CT扫描 (SCT) ,测量病灶增强幅度 ,并利用免疫组化技术检测VEGF。对病灶增强值、VEGF阳性表达及淋巴结转移情况进行统计学分析。结果　 30例肺癌病人CT增强值均数为 (36 .2 8± 6 .41 )HU ,VEGF阳性表达 2 1例 ,阴性表达 9例。VEGF在中晚期的阳性表达高于早期病人 (Ρ<0 .0 5) ,淋巴结转移组高于非淋巴结转移组 (Ρ <0 .0 5) ;癌灶增强值与VEGF阳性表达、肿瘤分期及淋巴结转移亦呈正相关。结论　NSCLC的CT增强程度能够反映肿瘤的血管生成 ,并与淋巴结转移密切相关 ,有助于肺癌的诊断、TNM分期 ,而且可以从肿瘤分子生物学行为方面补充目前肺癌分期方法的不足     

50例冠心病某些生化基础观测的临床诊断意义

对５０例冠心病患者进行某些生化基础观测，发现冠心病肾阴虚与糖耐量减低有关，肾阳虚患者尿１７－羟低於正常；而冠心病标证有其生化基础，与甘油三酯增高有密切相关。     

肺移植急性排斥反应及其控制实验研究

观察了大鼠实验性肺移植术后急性排斥反应的病理改变。异系间移植术后２ｄ，移植肺内小血管及支气管周围出现单核细胞浸润。４ｄ上述细胞浸润波及肺泡壁，导致肺泡壁增厚，肺内小静脉系及毛细血管管腔变窄，血流不畅。术后６ｄ，血液循环严重障碍处，肺泡完全坏死，环抱素Ａ可使上述排斥反应得到明显抑制。     

Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer

Summary Thirty-one patients with stage IIIB or IV non-small cell lung cancer (NSCLC) were treated with intravenous 10-EdAM on a weekly basis. The starting dose was 80 mg/m², with subsequent doses adjusted depending on evidence of toxicity. There were 20 men and 11 women with a median age of 58 years (range, 33–75). Response was evaluated in 30 patients, 5 with evaluable but not measurable tumors and 25 with measurable indicator lesions. There were no complete remissions; 3 patients achieved partial remission. Nine patients had a minor response, 6 showed no change, and 12 had progressive disease. Median survival for all 31 patients was 43 weeks (range, 12–65&#x002B;). During the first 3-week period, the 10-EdAM dose was reduced or withheld in 19 patients (because of stomatitis in 12, SGPT elevation in 3, skin rash in 2, and granulocytopenia in 2), escalated in 11 patients, and unchanged in 1 patient. A mean of 34–88 mg/m²of 10-EdAM (median, 50) was given per week during the first 5-week period. Myelotoxicity was infrequent and there was no significant nephrotoxicity. Considering the modest side effects of this treatment and the conservative dose-modification schedule which mandated substantial dose reductions, we conclude that 10-EdAM is a promising antitumor agent for NSCLC.     

肺囊肿样病变的X线诊断

作者报道28例经手术及病理证实的肺部囊性病变,其中21例为先天性,7例为后天性.x线表现可分为:①单发气囊腔.②多发性气囊腔.③单发液囊腔.④单或多发液气囊腔,内有液平面.⑤肺隔离症.讨论了形成机理以及与肺结核,肺脓肿,肺癌,转移性肺肿瘤,肺包虫囊肿等的x线鉴别诊断     

Subclinical pulmonary oedema and intermittent haemodialysis

It has been postulated that patients with chronic renal failure,even in the absence of cardiopulmonary symptoms, accumulateinterstitial pulmonary fluid, which is removed by haemodialysis.To test this hypothesis we used the indocyanine green (ICG)-heavywater double indicator dilution method to measure lung water,cardiac output, and central blood volume in relation to haemodialysis.Ten uraemic patients, without cardiopulmonary symptoms, wereinvestigated at the beginning and end, and 2 h after, a regulardialysis session. A group of 18 surgical patients about to undergoelective abdominal surgery served as controls. Despite normalgas exchange, central blood volume, and cardiac output at thestart of dialysis the mean (SD) lung water was significantlyhigher than in the control group [4.8 (0.9) compared with 3.6(0.7) ml/kg, P<0.001]. There was no correlation between weightgain between sessions of dialysis and the magnitude of lungwater at the start of dialysis. Lung water decreased (P <0.001)to the level of the control group in response to dialysis. Therewas no correlation between weight loss and reduction in lungwater induced by dialysis. In conclusion, we have verified thepresence of subclinical pulmonary oedema which was removed bydialysis in a group of patients with established renal failure.The variations in lung water cannot be explained by hydrostaticmechanisms alone.     

Computer-Assisted Design of an Implantable, Intrathoracic Artificial Lung

Abstract: A semiempirical mathematical model of convective oxygen transport is used to design a new, low pressure loss, implantable artificial lung that could be used as a bridge to lung transplantation in patients with advanced respiratory failure. The mass transfer and flow friction relations pertinent to the design of a cross–flow hollow fiber membrane lung are described. The artificial lung is designed to transfer over 200 ml/min of oxygen at blood flow rates up to 5 L/min. A compact design and a blood-side pressure loss of <15 mm Hg allows the device to be implanted in the left chest without the need for a prosthetic blood pump. Surgical implantation of the artificial lung would require the creation of inflow and outflow anastomoses. Oxygen would be supplied via an external source. Blood properties, operating conditions, and empirically determined mass transfer and flow properties are all specified and input into a computer program that numerically solves the design equations. Computer–generated values for the device frontal area, blood path length, and fiber surface area are thereby obtained. The use of this computer–assisted design minimizes the need for extensive trial–and–error testing of prototype devices. Results from in vitro tests of a prototype implantable lung indicate that the mathematical model we describe is an accurate and useful tool in the design of hollow fiber artificial lungs.     

Phase II trial of gallium nitrate,amonafide and teniposide in metastatic non-small cell lung cancer

Summary Fifty-five patients with metastatic non-small cell lung cancer (NSCLC) were entered into this phase II randomized study for evaluating three new agents: gallium nitrate, amonafide and teniposide. The patients had to have ECOG performance status 0 or 1, no prior chemotherapy, and adequate hematological, hepatic and renal functions. Forty-seven patients were eligible and evaluable. Fourteen were randomized to receive gallium nitrate, 18 to amonafide and 15 to teniposide. Seventy-four percent of eligible patients were male. The majority of patients (89%) had an ECOG performance status 1. ECOG grade 4 toxicity occurred twice in patients on gallium nitrate, seven times on amonafide and 18 times on teniposide. The cause of death was attributed to amonafide in one patient (from sepsis) and to teniposide in two patients (due to infection and leukopenia). There was no objective response in all the patients entered. The overall survival times ranged from 2 weeks to 156 weeks with a median of 23 weeks. There were no survival differences among the three treatment arms. We conclude that gallium nitrate, amonafide and teniposide are inactive in metastatic NSCLC and do not warrant any further testing in this disease.The contents of this study is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.